III. 1. What Is FMT? – The Science of the Therapy

FMT is not the transplant of a single bacterium but the rebuilding of an entire microbial ecosystem — just as a city cannot run on imported engineers alone.

More Than a Transplant – Rebuilding an Entire Microbial Ecosystem

Think of the gut microbiome as a city. In a functioning municipality, different professions are essential: engineers, sanitation workers, teachers, suppliers, security personnel. The city does not work with engineers alone — even the most skilled ones. What matters is not having the most of any one profession, but having the right mix, in the right proportions, doing the right work at the right time. The same principle governs the gut. Each microbial species occupies a functional role: some break down dietary fibre, others convert those breakdown products into short-chain fatty acids, others use those fatty acids as their own substrate, and yet others regulate inflammation, modulate immune responses, or compete against each other and opportunistic species. The health of the system depends not on the presence of any single 'beneficial' bacterium but on the integrity of the whole network.

This metaphor helps explain several things that matter clinically. First: why a multi-component probiotic taken without understanding the existing ecology can be unhelpful or counterproductive — a city cannot be rebuilt by importing hundreds of specialists if the roads, water supply, and energy infrastructure are absent. Second: why FMT takes weeks, not days — transplanting a new community requires rebuilding the metabolic infrastructure, not just repopulating the space. Third: why diet, sleep, and stress all affect outcomes — they are the city's energy supply, maintenance schedule, and civic order. Disrupting any one of them changes the conditions under which the microbial city can function.

A History Written in the Gut – FMT Through the Ages

Fecal microbiota transplantation (FMT) is the transfer of a carefully processed, diluted stool preparation—derived from a healthy, extensively screened donor—into the gastrointestinal tract of a recipient, in a defined form (e.g., enema or capsule), with the aim of restoring a disrupted microbial ecosystem. Microbiota Transfer Therapy (MTT), in contrast, refers to the broader therapeutic framework in which the patient’s environment and lifestyle are systematically aligned with the ecological requirements of the transplanted microbial matrix, thereby extending FMT into a comprehensive treatment protocol.

FMT is not a drug in the conventional sense. It does not deliver a single active molecule but rather an entire ecological community: hundreds of bacterial species, bacteriophages^[G], fungi, archaea, and their associated metabolites. This complexity is precisely its therapeutic strength. Where antibiotics or probiotics act on individual components of the microbial ecosystem, FMT attempts to restore the ecosystem as a whole – reintroducing colonization resistance^[G], functional diversity, and metabolic stability simultaneously.

The therapeutic principle underlying FMT rests on ecological competition. A dysbiotic or depleted microbiome^[G] lacks the community structure to resist opportunistic pathogens and sustain normal metabolic function. When a diverse donor community is introduced in sufficient quantity, it can outcompete residual pathogenic species, reoccupy ecological niches, and re-establish the functional relationships between microbial taxa and host physiology that characterize a healthy gut. This process is analogous to restoring a degraded habitat: success depends not only on which species are introduced, but on how many, in what sequence, and under what environmental conditions.

Current clinical evidence for the effectiveness of FMT is strongest in recurrent Clostridioides difficile infection (rCDI), where cure rates of 80–92% have been reported across multiple randomized controlled trials [7], [29]. In this condition, antibiotic-induced disruption has eliminated the colonization resistance that normally keeps C. difficile in check. A single high-dose FMT, administered via colonoscopy, is often sufficient to restore competitive equilibrium and prevent recurrence. The same principle – restoration of colonization resistance through microbial community transfer – is being applied to an expanding range of conditions, including inflammatory bowel disease (Inflammatory Bowel Disease: Crohn's disease and ulcerative colitis), metabolic syndrome, graft-versus-host disease, and recurrent urinary tract infections, though evidence in these areas is at earlier stages.

Not all patients and conditions respond to a single FMT session. The diversity and stability of the recipient's gut environment, the degree of prior antibiotic exposure, the underlying diagnosis, and the route and dose of administration all influence outcomes. This has driven the development of different FMT delivery formats and dosing protocols, each with distinct pharmacological and ecological properties.

Delivery Routes and Formulations – Not All FMT Is the Same

FMT can be administered through several routes, each of which delivers different volumes, microbial densities, and spatial distributions within the gastrointestinal tract. The choice of delivery route is a clinical decision that depends on the indication, patient condition, available infrastructure, and desired treatment duration.

Table 2 – Overview of FMT delivery routes and their clinical characteristics # Bacterial load, reach, and repeatability vary substantially between formats, which directly influences protocol design.

The Dose-Response Relationship – Why Density and Duration Both Matter

The modern framing of FMT rests on the holobiont^[G] approach: the host and its microbiome are understood as a single functional unit, so targeted modification of the microbial community produces system-level clinical effect [413]. A central insight from FMT research is that symptom suppression and lasting microbial colonization are governed by different biological mechanisms, and therefore require different dosing strategies. Understanding this distinction is essential for designing treatment protocols that achieve both short-term clinical response and long-term ecosystem stability.

High-dose FMT and symptom suppression When a large, concentrated microbial inoculum is introduced into a disrupted gut, it rapidly alters the ecological landscape. In the case of C. difficile infection, this works through several simultaneous mechanisms: competitive exclusion of C. difficile from mucosal attachment sites, reestablishment of colonization resistance through the reintroduction of bile acid-metabolizing bacteria which convert primary to secondary bile acids (gut bacteria–modified bile acids that reinforce colonisation resistance), inhibiting C. difficile germination), rapid restoration of SCFA^[G] production, and normalization of immune signaling. The high microbial density of colonoscopic FMT maximizes the probability that at least a critical subset of donor species will establish footholds before the immune system and residual pathogen community can mount a counter-response. Single high-dose colonoscopic FMT achieves clinical cure in approximately 80–92% of recurrent C. difficile cases in controlled trials, often within 48–72 hours [7].

The limitation of high-dose single-session FMT Despite its efficacy in acute suppression, a single high-dose FMT does not guarantee stable long-term colonization, particularly outside of C. difficile infection. Several factors limit sustained engraftment^[G]. First, the host immune system actively samples and responds to the incoming microbial community; a large single bolus may trigger stronger immune counter-regulation than repeated smaller doses. Second, ecological succession^[G] in the gut is a process – donor species must not only arrive but compete, adapt, form mutualistic relationships with host mucosa, and survive dietary and physiological fluctuations over weeks to months. Third, without ongoing reinforcement, the recipient's residual microbial signature – shaped by years of diet, genetics, and prior dysbiosis^[G] – can gradually reassert itself as the initially dominant donor community wanes.

Extended and repeated FMT for lasting colonization Oral capsule-based FMT enables what colonoscopy cannot: repeated dosing over weeks or months at lower per-session microbial density. This repeated-exposure approach mimics the natural process of microbial succession more closely than a single bolus. Each dose provides a renewed inoculum, preventing the competitive rebound of dysbiotic species while allowing donor taxa to progressively establish deeper ecological relationships with the host mucosa, immune system, and dietary substrate environment. Studies in IBD (inflammatory bowel disease: Crohn's disease and ulcerative colitis) and metabolic conditions consistently show that multiple FMT sessions, administered over 6–8 weeks or longer, produce more durable microbiome changes than single-session approaches. The mechanism appears to involve progressive immune tolerance to donor microbiota, stepwise ecological niche filling, and cumulative shifts in host–microbiota metabolic interactions.

Phage dynamics as a hidden variable Beyond bacteria, FMT preparations contain bacteriophages – viruses that specifically infect bacteria. Phages influence which bacterial species can establish in the recipient's gut by selectively lysing competing strains, and emerging evidence suggests that phage engraftment patterns differ between colonoscopic and capsule-based delivery [30]. High-dose single-session FMT delivers a large phage inoculum simultaneously with bacteria, which may rapidly reshape bacterial community dynamics. Repeated low-dose delivery allows more gradual phage–bacterium co-evolution in the new environment, potentially supporting more stable long-term outcomes. This is an active area of research, and current evidence does not yet permit precise protocol recommendations based on phage dynamics alone.

Dosing Intensity and Severity in C. diificile infections: The Hyperbolic Treatment Model

Not all dysbiosis requires the same intensity of FMT. The clinical response to FMT is closely related to the depth of the existing microbial disruption: a mildly depleted microbiota requires a different approach than one that has been severely damaged over months or years of antibiotic use, hospitalization, or recurrent infection.

MicroBiome Bank's clinical protocol draws on a four-scale composite severity assessment to guide dosing intensity. The component scales — the Zar scale, the ATLAS model, the VA Hines scale, and the CARDS (Clostridioides difficile Associated Risk of Death Score) system — each capture different dimensions of severity: symptom burden, laboratory parameters, prior treatment failure, and systemic risk. By synthesising these into a composite score, the clinical team can determine not only whether FMT is indicated, but how intensively it should be delivered.

The resulting dosing model is described as a hyperbolic treatment protocol: the treatment curve starts high and descends as the symptoms ease. In the early induction phase, capsule density and frequency are at their maximum — sufficient to overcome the colonisation resistance of a severely dysbiotic environment. As engraftment stabilises and clinical markers improve, dosing is progressively reduced. The step-down follows the patient's biological trajectory, not a fixed calendar.

This approach matters because a standard dose applied to a severely depleted gut often produces only transient effects. The incoming donor community finds insufficient ecological infrastructure — no mucosal niche, no substrate chain, no cooperative partners — and is outcompeted before it can establish. The flooding approach (sustained high-density inoculation) maintains continuous colonisation pressure until the ecological conditions shift in favour of the transplanted community.

For patients with mild or early-stage dysbiosis, a lower starting dose is appropriate: the existing microbiota, though disrupted, still provides scaffolding for the incoming community. For moderate cases with prior treatment failure or persistent relapse, an intermediate protocol applies. Severe cases — characterised by very low microbial diversity, active pathobiont dominance, or compromised mucosal barrier — require the most intensive initial phase, followed by a carefully managed descent.

This severity-guided, individually calibrated model is one of the core distinctions between FMT used as an ecological restoration strategy and FMT used as a single-event procedure. The goal is not to deliver microbes once — it is to create and sustain the conditions under which a new, stable microbial community can take root.

The FMT Compatibility Assessment – A Biological Probe for Donor-Recipient Matching

Not all donor-recipient combinations produce equivalent FMT outcomes. For chronic, non-CDI conditions – including inflammatory bowel disease, metabolic syndrome, and functional gastrointestinal disorders – a preceding compatibility assessment phase is integrated before full induction, modifying the protocol into a four-phase architecture. The microbiota is an immunologically active ecosystem: the recipient's mucosal immune system, existing microbial community, and genetic background all influence how a specific donor preparation is received. In a subset of patients, a given donor preparation may trigger an exacerbation of symptoms, an inappropriate inflammatory response, or simply fail to engraft – even when the donor material meets all standard quality criteria. This donor-recipient incompatibility is one of the most clinically important variables in FMT outcomes for chronic conditions, yet it cannot be reliably predicted from pre-treatment laboratory parameters alone.

To address this, MicroBiome Bank employs a compatibility assessment procedure that is conceptually analogous to the biological probe used in blood transfusion medicine. In transfusion practice, a small volume of blood is administered slowly at the bedside before proceeding with the full transfusion, allowing the clinical team to detect acute hemolytic or hypersensitivity reactions in real time, typically within minutes. The FMT compatibility assessment follows the same logic but operates on a different timescale and through different mechanisms: rather than detecting antibody-mediated hemolysis in minutes, it detects adverse microbial-immune interactions over days.

The MicroBiome Bank compatibility assessment follows a structured, repeatable protocol consisting of four sequential 8-day cycles. In each cycle, the patient receives a single donor preparation in low-dose capsule form on five consecutive days, followed by a three-day washout period during which no FMT capsules are administered. This 5+3 day structure is designed to allow sufficient microbial exposure for a symptomatic and functional response to develop, while providing a washout interval adequate for the low-dose preparation to clear the gastrointestinal tract before the next LOT is introduced. At standard capsule doses used in this phase, luminal transit of the microbial content is typically complete within 24–72 hours in patients with normal intestinal motility. In patients with significantly slowed gastrointestinal transit – for example, due to opioid use, autonomic neuropathy, or obstructive IBD complications – the clinical team may extend the washout period beyond three days at their discretion.

Over the course of four cycles, up to four different donor preparations can be systematically assessed. Each preparation is selected from the available MicroBiome Bank donor library based on prior engraftment outcome data and adverse event profiles accumulated from previous recipients. Donor preparations with consistently high engraftment rates across diverse recipient profiles – reflecting the 'super-donor^[G]' phenomenon documented in the FMT literature [31], [32], [8] – are prioritized as first-line candidates.

The primary analytical tool throughout the compatibility assessment is the structured Food and Symptom Diary. Patients record daily stool frequency and consistency (Bristol Stool Scale), abdominal symptoms (bloating, pain, cramping on a 0–10 scale), energy level, mood, and sleep quality. Food intake is recorded to allow the clinical team to distinguish donor-preparation-related symptomatic changes from dietary fluctuations or other confounding variables. At the end of the 32-day testing phase, the diary data is reviewed by the clinical team to assess whether a preparation produced a meaningful advantegous signal, a neutral response, or an adverse one. This patient-reported outcome methodology is consistent with validated approaches used in FMT clinical research [32], [33] and provides the primary evidence base for donor selection decisions.

Upon completion of the assessment, and before proceeding to the induction phase, patients complete a structured Exposome^[G] Assessment Questionnaire. The concept of the exposome – encompassing the totality of environmental exposures across an individual's lifetime, including diet, medications, occupational factors, stress, sleep patterns, physical activity, and chemical exposures – has gained substantial scientific traction as a framework for understanding individual variation in health outcomes [10], [11]. In the FMT context, exposome profiling serves a specific clinical decision-support function: it systematically maps the environmental factors currently present in the patient's life that are likely to either facilitate or impede FMT engraftment and long-term microbiota stability. Factors identified as barriers – such as ongoing high-dose antibiotic use, severe sleep disruption, a highly processed low-fiber diet, or chronic psychological stress – can be addressed prior to or concurrent with induction, substantially improving the ecological conditions into which the donor microbial community will be introduced. Factors identified as facilitators – such as regular physical activity, adequate dietary fiber intake, or stable circadian patterns – are reinforced and optimized. The exposome assessment therefore does not delay treatment; it ensures that the subsequent induction phase operates under the most favorable host conditions achievable.

It is important to be precise about the mechanistic analogy to blood transfusion compatibility testing. In transfusion medicine, incompatibility is primarily immunological and structured: ABO and Rh blood group mismatches trigger predictable, acute complement-mediated hemolysis. In FMT, incompatibility is ecological and immunological simultaneously, and it is less predictable. Adverse reactions may reflect host immune rejection of specific donor microbial taxa, competitive interference between donor and residual recipient species, exacerbation of mucosal inflammation by specific microbial metabolite profiles, or mismatch between donor SCFA production capacity and recipient mucosal substrate requirements. The compatibility assessment therefore functions not as a binary pass/fail test – as blood cross-matching does – but as a calibrated clinical observation window that reduces the probability of proceeding to full induction with an unsuitable donor preparation.

For patients with C. difficile infection, the compatibility assessment phase is generally omitted. The clinical urgency of active CDI – particularly recurrent CDI, where each episode increases morbidity, risk of complications, and gut ecosystem damage – justifies proceeding directly to high-dose induction. In this context, the established efficacy of colonoscopic FMT in CDI (80–92% cure rates in controlled trials) is sufficient evidence that the ecological disruption caused by CDI itself overrides donor-specific compatibility as the primary determinant of outcome. In non-CDI chronic conditions, where treatment urgency is lower and the recipient's residual microbiome is more ecologically stable, compatibility assessment adds clinically meaningful information at acceptable cost in time and resources.

Table 3 – FMT treatment architecture by phase # Phase 0 (compatibility assessment, 4 × 8-day cycles) applies to non-CDI patients only; for recurrent C. difficile infection, treatment begins directly at Phase 1 induction. Minimum transfer duration: 60 days for non-CDI conditions, 30 days for CDI, measured from the start of induction. Phase transitions are guided by clinical response, stool pattern normalization (Bristol Stool Scale), Food and Symptom Diary review, and physician assessment.

The induction phase exploits the ecological principle of priority effects: the first community to occupy a disrupted niche at sufficient density gains a competitive advantage over later arrivals [34]. By delivering a large, diverse donor inoculum early in treatment, the induction phase maximizes the probability that donor taxa will establish before the recipient's residual dysbiotic community can reorganize. This is where colonoscopic FMT or intensive capsule loading is most relevant clinically.

Understanding the microbial metabolic chain helps explain why engraftment takes time and why stability can be fragile in the early weeks. Each species in the gut operates within a metabolic relay: it takes in substrates, transforms them, and releases outputs that serve as inputs for the next species in the chain. The rate at which each species completes this transformation — its operational time — determines whether the chain flows smoothly or accumulates bottlenecks. If a key species is too slow, or its population collapses, the metabolites it was supposed to produce go missing; the downstream species that depend on them lose their substrate and also decline. What looks like a single bacterial absence is often a cascade: one gap in the relay disrupts the entire sequence.

This has a direct practical implication for FMT. When donor bacteria are introduced into a severely dysbiotic gut, they do not immediately slot into an existing relay. They may have the functional capacity — the genetic 'know-how' — but the relay partners they need, the substrates they require, and the spatial niches they must occupy may not yet exist. Rebuilding the chain takes time proportional to the depth of the disruption. This is one reason why the minimum effective duration for non-CDI conditions is at least 60 days: the first weeks establish the initial colonisation; the subsequent weeks allow metabolic partnerships to form and the chain to begin operating at functional capacity. It is also why dietary fiber, timing of meals, and sleep quality exert such measurable effects — they directly supply or withhold the substrates that keep the relay running.

The consolidation phase shifts the objective from displacement to integration. Repeated moderate-dose capsule FMT sustains donor species presence while the host immune system progressively adapts. The gut mucosal immune system – particularly lamina propria (connective tissue layer beneath the intestinal epithelium) dendritic cells and regulatory T cells (immune cells that suppress inflammation and promote tolerance) – must develop tolerance to the incoming microbial community. This process unfolds over weeks, not days, which explains why single-session FMT often produces incomplete engraftment in conditions with active mucosal immune dysregulation, such as Crohn's disease or ulcerative colitis.

The minimum transfer duration of 60 days for non-CDI conditions, and 30 days for recurrent C. difficile infection, reflects the biological timescale of stable microbiota remodeling. This is not an arbitrary clinical convention. A 2017 randomized controlled trial demonstrated that eight weeks of intensive FMT in ulcerative colitis produced significantly higher remission rates than two weeks, directly establishing a dose-duration relationship in a chronic inflammatory condition [35]. A 2015 randomized controlled trial similarly found that a greater number of FMT administrations was associated with higher response rates in UC [31]. For CDI, the rapidity of ecological disruption caused by the pathogen itself accelerates the response to FMT, and clinical cure is typically observed within days to weeks of induction; however, a 30-day minimum consolidation phase reduces the risk of late recurrence driven by residual spore burden or incomplete restoration of colonization resistance. Both minimum durations represent floors, not ceilings: patients with complex, refractory, or immunocompromised conditions may require substantially longer transfer phases, determined by clinical response monitoring rather than fixed timelines.

The step-down phase mirrors the principle of ecological maturation. As the donor community becomes more deeply integrated into the host's gut ecosystem – supported by sustained dietary fiber intake, stable sleep and circadian patterns, reduced inflammatory load, and favorable medication adjustments – external reinforcement can be reduced. The goal is not indefinite FMT administration but the emergence of an autonomous, self-sustaining microbial community that no longer requires continuous external support. Step-down schedules are individualized: patients with severe underlying immunosuppression, ongoing antibiotic exposure, or refractory inflammatory conditions may require longer maintenance phases.

This guide accompanies the reader through all three phases. The chapters that follow address the preparation steps, procedural expectations, monitoring parameters, and lifestyle interventions that support each phase of treatment. The lifestyle modifications described in later chapters are not optional additions to FMT – they are the environmental scaffolding that determines whether the transplanted community will thrive or fade.

Microbiota Effects

• FMT introduces a complete donor microbial community into the recipient gut; the degree of engraftment – the proportion of donor taxa that establish durably – is variable and depends on recipient microbiota composition, immune status, indication, and dosing protocol [8], [34].
• High-dose single-session FMT (colonoscopy) produces rapid, large-scale shifts in microbial community structure, detectable within 24–72 hours, with partial convergence toward donor matrix composition in most recipients; long-term donor engraftment at species level varies from approximately 20–80% depending on the condition and individual.
• Donor-recipient compatibility – the degree to which a specific donor's microbial community engrafts and is tolerated in a specific recipient – is a clinically significant variable that cannot be fully predicted from pre-treatment laboratory parameters; it is influenced by recipient immune profile, gut mucosal status, residual microbiota composition, and the specific metabolic and immunogenic properties of the donor preparation.
• The 'super-donor' phenomenon – whereby certain donor preparations consistently produce higher engraftment rates and better clinical outcomes across diverse recipients – is documented across multiple FMT trials in inflammatory bowel disease and C. difficile infection [31], [35], [8]; its mechanistic basis includes donor microbiota diversity, specific keystone species abundance, bacteriophage^[G] community composition, and metabolite profile of the matrix.
• Repeated low-dose FMT (capsule protocols over weeks) is associated with more progressive but potentially more stable microbiota shifts, with some studies reporting higher proportional donor engraftment after 6–8 weeks compared to single colonoscopic sessions, particularly in inflammatory bowel disease.
• FMT restores colonization resistance – the capacity of the microbiota to prevent pathogen overgrowth – primarily by reintroducing taxa that produce bacteriocins, compete for nutrients and attachment sites, and restore secondary bile acid (bile acids chemically modified by gut bacteria, important for colonisation resistance) metabolism inhibitory to C. difficile and other opportunistic pathogens.
• Engraftment of donor bacteriophages occurs in parallel with bacterial transfer and may persist longer than bacterial donor taxa in some individuals; phage community shifts contribute to the restructuring of the recipient's bacterial community independently of direct bacterial seeding.
• FMT shifts SCFA production profiles, typically increasing butyrate (a short-chain fatty acid that serves as the primary energy source for colonocytes and helps reduce inflammation) and propionate (a short-chain fatty acid involved in hepatic metabolism, gluconeogenesis, and appetite regulation) relative to pre-treatment levels, though the magnitude and duration of these shifts depend on concurrent dietary fiber intake and the specific donor community transferred.
• Mucosal immune normalization – including increased regulatory T cell (immune cells that suppress excessive immune responses and maintain tolerance) abundance, reduced pro-inflammatory cytokine signaling (IL-6, TNF-α, IL-17), and restoration of secretory IgA – has been observed following FMT in IBD and C. difficile infection [7], [31], [35]; these changes occur over weeks to months rather than immediately post-transfer.
• The gut-brain axis^[G] is modulated secondarily: normalization of microbial tryptophan^[G] metabolism, GABA precursor production, and vagal afferent signaling may contribute to improvements in mood, stress tolerance, and autonomic function observed in some FMT recipients, though causal evidence in humans remains limited.
• Individual donor-recipient compatibility influences engraftment and clinical outcomes; some donors consistently produce higher engraftment rates across recipients ('super-donors'), a phenomenon currently under investigation as a basis for donor-matching algorithms in clinical practice.
• FMT does not permanently overwrite the recipient's microbiome; without ongoing environmental support (diet, lifestyle, reduced inflammatory burden), partial reversion toward the pre-FMT community structure can occur over 12–24 months, underscoring the importance of the lifestyle modifications described in this guide.

Patient Guidance

• Discuss your diagnosis and treatment goals with your physician before FMT: understand which phase of the protocol you are entering and what the expected timeline is.
• If you are in the compatibility assessment phase (Phase 0): the full phase consists of four 8-day cycles. In each cycle, you will take capsules of one donor preparation for five days, followed by three days without capsules. This is not a delay in your treatment – it is an integral part of it. The data collected during this phase directly determines which donor preparation will be used in your induction and consolidation phases, and significantly improves the probability of a durable positive outcome.
• Keep your Food and Symptom Diary as precisely as possible during Phase 0. Record your stool frequency and consistency using the Bristol Stool Scale each day, rate your abdominal symptoms (bloating, pain, cramping) on a 0–10 scale, and note your energy level, mood, and sleep quality. Record everything you eat and drink. This diary is not a formality – it is the primary clinical tool your physician uses to assess donor-preparation compatibility and make the selection decision.
• Upon the request of your physician complete the Exposome Assessment (D•E•M•I) questionnaire thoroughly and honestly. The questionnaire covers your diet, sleep patterns, physical activity, stress levels, medication use, occupational exposures, and other lifestyle factors. Its purpose is to identify environmental conditions in your life that may either help or hinder FMT success. Your clinical team uses this information to optimize the conditions around your induction phase; factors identified as barriers can often be partially addressed before treatment begins.
• Understand that donor selection in non-CDI conditions is informed by prior outcome data: your clinical team uses accumulated engraftment and clinical response records from previous recipients to identify donor preparations most likely to be compatible with your profile. This is evidence-informed clinical matching, not guesswork.
• If you are scheduled for colonoscopic FMT (Phase 1 induction): follow the bowel preparation instructions provided by your clinical team precisely; an inadequately prepared colon reduces engraftment probability.
• During the induction phase, prioritize rest and easily digestible, low-fermentation nutrition (see III.1 Dietary Fiber – Version B); your gut environment is being restructured and additional fermentative stress should be minimized.
• Do not discontinue prescribed medications without consulting your physician, even if you feel acutely improved after the first FMT session; dysbiotic rebound can occur within days if the induction phase is not followed by consolidation.
• During the consolidation phase (capsule FMT), take capsules at the time and frequency prescribed; capsule FMT is most effective when the gut environment is consistently supportive – stable meal timing, adequate fiber, and sufficient sleep all reinforce the incoming microbial community.
• Report any fever above 38°C, blood in stool, severe abdominal pain, or systemic symptoms immediately; these may indicate adverse reactions requiring clinical evaluation.
• Do not compare your response timeline to other patients; engraftment rates, symptom resolution speed, and phase durations are highly individual and depend on your diagnosis, immune profile, and baseline microbiome.
• Understand the step-down phase as a sign of progress, not withdrawal; the decreasing capsule frequency in Phase 3 reflects growing microbial ecosystem autonomy, not reduced treatment efficacy.
• The lifestyle modifications described in subsequent chapters of this guide – dietary fiber, meal timing, sleep, physical activity, and stress management – are not supplementary; they are the environmental conditions that determine long-term FMT success. Engage with them actively from Day 1 of treatment.

References

[7] van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013. Link

Open-label RCT in patients with recurrent C. difficile infection comparing duodenal donor faeces infusion (after short vancomycin + bowel lavage) with standard 14-day vancomycin, with or without bowel lavage. The primary endpoint was diarrhoea resolution without relapse at 10 weeks. The trial was stopped early at interim analysis: 13/16 patients (81\%) in the FMT arm achieved resolution after a single infusion, substantially exceeding both vancomycin arms. Establishes FMT as superior to antibiotic monotherapy for recurrent CDI and provides the landmark evidence base for FMT clinical translation.

[8] Ianiro G, Punčochář M, Karcher N et al. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat Med. 2022. Link

Integrated shotgun metagenomic meta-analysis of 226 donor–recipient triads across eight disease types examining microbial engraftment dynamics after FMT. Higher donor strain engraftment was significantly associated with clinical success (P=0.017). Engraftment was greater with multi-route delivery (capsule plus colonoscopy) and in antibiotic-treated recipients with infectious disease versus antibiotic-naïve patients with noncommunicable disease. Bacteroidetes and Actinobacteria (including Bifidobacteria) showed higher engraftment than most Firmicutes. A cross-dataset machine-learning model predicted post-FMT species presence with AUROC 0.77.

[10] Wild, C. P. Complementing the Genome with an 'Exposome': The Outstanding Challenge of Environmental Exposure Measurement in Molecular Epidemiology. Cancer Epidemiol Biomarkers Prev. 2005. Link

Wild's seminal 2005 Cancer Epidemiology, Biomarkers and Prevention commentary introduces the concept of the 'exposome' to complement genomic measurement in molecular epidemiology. He argues that lifetime environmental exposures, including diet, lifestyle, infections, pollutants and endogenous processes, are as important as the genome in determining disease risk, but are systematically under-measured. The article calls for technologies and study designs capable of capturing exposures across the life course with sensitivity comparable to high-throughput genomics. Wild outlines internal, specific-external and general-external exposome domains. The concept has since shaped large cohort studies and biomarker-based exposure assessment, including microbiome-related work.

[11] Rappaport SM, Smith MT. Epidemiology. Environment and Disease Risks. Science. 2010. Link

Conceptual statement arguing that a new epidemiological paradigm is required to assess how lifetime cumulative exposure to environmental factors affects chronic disease risk. Calls for systematic exposome-level analysis beyond single-exposure designs.

[29] Peery AF, Kelly CR, Kao D et al. AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. Gastroenterology. 2024. Link

Review of patient-reported outcome (PRO) instruments for disorders of gut–brain interaction (DGBI), where symptom assessment is the principal modality given the absence of endoscopic, radiologic, or biomarker findings. Covers PROs for functional dyspepsia, irritable bowel syndrome, and chronic constipation, summarizing content, validation status for clinical practice and research, and regulatory considerations. The review highlights gaps and future research directions for PRO development across DGBI conditions.

[30] Zuo T, Wong SH, Lam K et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut. 2018. Link

Investigation of enteric virome alterations in 24 CDI subjects and 20 healthy controls using ultra-deep metagenomic sequencing of virus-like particles plus 16S rRNA bacterial profiling. Nine CDI patients treated with FMT and five treated with vancomycin were longitudinally assessed for virome and bacteriome changes in relation to treatment response. The data link viral transfer during FMT — particularly bacteriophages — with clinical resolution of CDI, suggesting that phage transfer contributes to the therapeutic effect beyond bacterial engraftment alone.

[31] Moayyedi P, Surette MG, Kim PT et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015. Link

Placebo-controlled randomized trial in patients with active ulcerative colitis without infectious diarrhoea. Participants were randomized to FMT (50 mL enema from healthy anonymous donors, n=38) or placebo water enema (n=37) once weekly for 6 weeks; patients, clinicians, and investigators were blinded. The trial assessed safety and efficacy of FMT for inducing remission in UC, demonstrating that FMT can produce clinical and endoscopic improvement beyond placebo in a subset of patients. Findings support FMT as a microbiota-modulating option in active UC while highlighting variable individual response.

[32] Paramsothy S, Nielsen S, Kamm MA et al. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. Gastroenterology. 2019. Link

Double-blind RCT in 81 patients with active ulcerative colitis randomized to intensive multidonor FMT or placebo enemas 5 days/week for 8 weeks after an initial colonoscopic infusion. FMT patients received blended stool from 3–7 unrelated donors; placebo patients were eligible for open-label FMT afterward. 314 fecal samples were collected across screening, treatment, and 8 weeks post-therapy to identify bacterial taxa and metabolic functions associated with response. The study identifies microbial and metabolite signatures that predict FMT response in UC, supporting donor selection and response stratification.

[33] Porcari S, Benech N, Valles-Colomer M et al. Key determinants of success in fecal microbiota transplantation: from microbiome to clinic. Cell Host Microbe. 2023. Link

Review of determinants of FMT success spanning donor and recipient factors (microbiome diversity and composition, immune status, host genetics) and procedural factors (faecal amount, infusion number, route of delivery, adjuvant treatments). Clinical success appears closely linked to the degree of donor microbial engraftment. The authors argue that integrating cutting-edge microbiome technologies with revised conceptual frameworks — and tighter coupling of laboratory and clinical workflows — will improve FMT protocols and outcomes across indications beyond CDI.

[34] Smillie CS, Sauk J, Gevers D et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe. 2018. Link

Strain-level analysis of FMT for recurrent Clostridium difficile infection introducing Strain Finder, a method for inferring strain genotypes and tracking engraftment longitudinally. A statistical model predicted species-level engraftment largely from donor abundance and pre-FMT recipient phylogeny. Donor strains within a species engrafted in an all-or-nothing manner, and previously undetected strains frequently colonized recipients. The work defines the determinants of bacterial engraftment in human FMT and provides a framework for predicting graft outcomes.

[35] Paramsothy S, Kamm MA, Kaakoush NO et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017. Link

Paramsothy and colleagues report the FOCUS trial, a landmark Lancet 2017 randomised placebo-controlled study of multidonor intensive fecal microbiota transplantation (FMT) in active ulcerative colitis. Eighty-one adults with mild-to-moderate active UC received either pooled-donor FMT or placebo enemas, with an induction colonoscopic infusion followed by enemas five days per week for eight weeks. The primary endpoint of steroid-free clinical remission with endoscopic remission or response at week 8 was achieved in 27% of FMT versus 8% of placebo recipients (p=0.021). Microbial diversity increased in responders, with specific Fusobacterium decreases and Eubacterium and Roseburia increases. The trial established multidonor, intensive-dose FMT as a credible therapeutic strategy in UC.

[413] Cammarota G, Ianiro G, Bibbò S et al. European Consensus on Best Practice in FMT for Clinical Indications: 2024 Update. Gut. 2024. Link

Cammarota, Ianiro, Bibbò and colleagues' 2024 Gut paper presents the European Consensus on Best Practice in FMT for Clinical Indications, 2024 Update. Convened by the European FMT Working Group, the consensus updates the 2017 guidance with new evidence on rCDI (Grade 1A recommendation, primary therapy after first or second recurrence), expanded research-grade indications (decolonisation of MDROs, IBD, hepatic encephalopathy, IBS), donor screening alignment with EU SoHO Regulation, standardised stool processing and biobanking, and pharmacovigilance/traceability requirements. The document also addresses oral encapsulated FMT, defined microbial consortia, and the regulatory landscape after Rebyota/Vowst approvals. It is the definitive European clinical FMT reference for 2024–2027.